|
|
|
|
| LEADER |
01188nam a2200265 u 4500 |
| 001 |
EB002000974 |
| 003 |
EBX01000000000000001163875 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 100 |
1 |
|
|a Ho, Chuong
|
| 245 |
0 |
0 |
|a Eltrombopag for the treatment of aplastic anemia
|h Elektronische Ressource
|b a review of clinical and cost-effectiveness
|c Chuong Ho, Sarah Visintini
|
| 246 |
3 |
1 |
|a Eltrombopag for aplastic anemia
|
| 250 |
|
|
|a Version 1.0
|
| 260 |
|
|
|a Ottawa
|b CADTH
|c 2018, July 09, 2018
|
| 300 |
|
|
|a 1 PDF file (7 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 700 |
1 |
|
|a Visintini, Sarah
|e [author]
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH rapid response report: summary with critical appraisal
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK537722
|3 Volltext
|
| 082 |
0 |
|
|a 330
|
| 520 |
|
|
|a This Rapid Response report aims to review the comparative clinical and cost-effectiveness of eltrombopag versus other options for the treatment aplastic anemia (AA)
|